About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 16227 record(s)
Req # A-2023-001329
Correspondence relating to any Abbreviated New Drug Submission (ANDS) filed since January 1, 2022 where the medicinal ingredient is mesalazine and which discusses the route of administration.Organization: Health Canada
July 2024
Req # A-2023-001331
Advise whether the Mesalazine Abbreviated New Drug Submission (ANDS) has received either: a Screening Acceptance Letter; a Notice of Deficiency (NOD); a Notice of Non-Compliance (NON); a NOD-Withdrawal (NOD-W); or a NON-Withdrawal (NON-W).Organization: Health Canada
July 2024
Req # A-2023-001458
The Product Information Template: Regulatory Enrollment Process for the Third Desmopressin Abbreviated New Drug Submission (ANDS), setting out the proposed indication(s)/use(s) of the drug product.Organization: Health Canada
July 2024
Req # A-2023-001470
The regulatory letter sent to Naked Organs Ltd. in October 2023.Organization: Health Canada
July 2024
Req # A-2023-001481
Documents and records containing information regarding the mock-ups of every label to be used in connection with the Degarelix Abbreviated New Drug Submission (ANDS).Organization: Health Canada
July 2024
Req # A-2023-001482
The Drug Master File (MF) of the Degarelix Abbreviated New Drug Submission (ANDS).Organization: Health Canada
July 2024
Req # A-2023-001484
The Abbreviated New Drug Submission (ANDS) cover letter of the company (sponsor) who submitted the Degarelix ANDS.Organization: Health Canada
July 2024
Req # A-2023-001604
The most recent Certified Product Information Document (CPID) submitted for the Semaglutide Abbreviated New Drug Submission (ANDS).Organization: Health Canada
July 2024
Req # A-2024-000001
All records related to the clarification requests and to the response received from Pfizer, including discussions and consultations between Health Canada’s Biologic and Radiopharmaceutical Drugs Directorate (BRDD) staff on the matter of the presence…Organization: Health Canada
July 2024
Req # A-2024-000150
All emails and email attachments held by the media relations team that were created between March 1, 2024 and May 7, 2024 mentioning "Highly pathogenic avian influenza" (HPAI) in cattle and/or bovine avian influenza.Organization: Health Canada
July 2024